Erytech Pharma – About the Company

Erytech Pharma is a biopharmaceutical company developing innovative treatments for oncology, with three ongoing clinical trials for lead candidate GRASPA in patients with acute leukemia. GRASPA is a pioneering approach for delivering cancer-fighting agents to patients by encapsulation in red blood cells (RBCs) to minimize unwanted side effects. GRASPA specifically contains L-asparaginase, which is a potent anti-cancer agent that is not commonly used in adults due to a high rate of side effects in the population. The market for L-asparaginase is currently limited to pediatric patients, and a product with a more favorable safety profile has the potential to expand use into adults, seniors, and relapsed patients.

Erytech is testing GRASPA in three ongoing clinical trials. A European Phase III trial in relapsed adults and children with acute lymphoblastic leukemia (ALL) is expected to be completed in the third quarter of 2014. A Phase I/II trial with adult ALL patients is ongoing in the US, and a European Phase IIb trial in elderly AML patients received a positive Data and Safety Monitoring Board review in November 2013. Erytech is also planning a Phase II trial with GRASPA in pancreatic cancer that is expected to launch in the second quarter of 2014. Additional uses of the RBC technology are under preclinical investigation and include cancer vaccination and immune tolerance applications.